Amoxicillin Market To Reach USD 4,962.6 Million By 2026 | Reports And Data
04 nov. 2019 11h42 HE
|
Reports and Data
New York, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Government initiatives for the reach of amoxicillin for treating children with bacterial pneumonia, collaborations for technical advancements, and...
How to Prevent Common Skin Infections at the Gym; American Academy of Dermatology
08 janv. 2019 14h00 HE
|
American Academy of Dermatology
ROSEMONT, Ill., Jan. 08, 2019 (GLOBE NEWSWIRE) -- As more people flock to the gym for their New Year’s resolutions, dermatologists from the American Academy of Dermatology are offering words of...
Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
02 mars 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting
14 juin 2016 12h30 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, June 14, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that...
Melinta Therapeutics’ Baxdela™ Successfully Achieves Endpoints in Confirmatory Phase 3 Study in Patients with Hospital-Treated Skin Infections
12 mai 2016 08h00 HE
|
Melinta Therapeutics
New Haven, CT, May 12, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced top-line results...
Melinta Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
05 janv. 2016 08h00 HE
|
Melinta Therapeutics
New Haven, CT, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will be providing a corporate update at...
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections
19 mai 2015 16h00 HE
|
Melinta Therapeutics
New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative
impact of obesity on patients' recovery from acute bacterial skin
and skin structure...